Related Experiment Videos
Chronic animal toxicity studies on antineoplaston A2
Drugs Under Experimental and Clinical Research
|January 1, 1986
Summary
Antineoplaston A2 administered daily to mice for 270 days showed no toxic effects across various dosages. This preclinical study indicates a favorable safety profile for Antineoplaston A2 in animal models.
Area of Science:
- Pharmacology
- Toxicology
- Preclinical Research
Background:
- Antineoplaston A2 is a compound investigated for potential therapeutic applications.
- Understanding the safety profile of novel compounds is crucial before human trials.
Purpose of the Study:
- To evaluate the toxicological effects of Antineoplaston A2 in a rodent model.
- To determine the safety of chronic daily administration of Antineoplaston A2.
Main Methods:
- 160 mice (equal sexes) received daily intraperitoneal injections of Antineoplaston A2 at 107 mg/kg, 646 mg/kg, or 1300 mg/kg for 270 days.
- A control group received no treatment.
- Animals were observed for up to 365 days, with physical, gross pathological, and microscopic examinations performed at scheduled intervals.
Main Results:
- No adverse toxic effects were observed in mice treated with Antineoplaston A2 at any of the tested dosage levels.
- Comprehensive examinations revealed no signs of toxicity throughout the 270-day administration period and subsequent observation.
Conclusions:
- Daily intraperitoneal administration of Antineoplaston A2 at doses up to 1300 mg/kg for 270 days is safe in mice.
- The study supports the lack of observed toxicity for Antineoplaston A2 in this preclinical setting.